OTCMKTS:INSV InSite Vision (INSV) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free INSV Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume650,138 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get InSite Vision alerts: Email Address Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About InSite Vision Stock (OTCMKTS:INSV)InSite Vision Incorporated is an ophthalmic product development company that offers ophthalmic pharmaceutical products. The Company's portfolio of products is based on its DuraSite sustained drug delivery technology. The Company's offerings include BromSite and DexaSite. DuraSite sustained drug delivery technology is a synthetic polymer-based formulation to extend the residence time of a drug relative to conventional topical therapies. DuraSite enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a variety of drug candidates. The Company is engaged in the research and development and commercial support with the DuraSite drug delivery technology for the following topical products: AzaSite, Besivance, BromSite, DexaSite, AzaSite Plus and ISV-101.Read More Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here INSV Stock News HeadlinesApril 30, 2024 | finance.yahoo.comQ4 2023 Streamline Health Solutions Inc Earnings CallApril 30, 2024 | msn.comInnovative Features Making the Ulike Air 10 Superior to the Previous ModelsMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 29, 2024 | msn.comRumors swirl that Apple plan to use ChatGPT to power AI features in iOS 18April 29, 2024 | bloomberg.comEU Sets New Rules for Apple's iPadApril 29, 2024 | markets.businessinsider.comInterDigital’s Doug Castor Elected Co-Chair of the ATIS Next G Alliance Steering GroupApril 27, 2024 | entrepreneur.comWhat's the Next Big Trend in Multimedia Content for Startups?April 26, 2024 | msn.comCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli LillyMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 26, 2024 | finance.yahoo.comDecoding Meta Platforms Inc (META): A Strategic SWOT InsightApril 25, 2024 | finance.yahoo.comNanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical AdvisorApril 25, 2024 | msn.comBecky Lynch Discusses How WWE Is Different These DaysApril 23, 2024 | msn.comMizzou hires Memphis’ Laird Veatch as new athletic directorApril 23, 2024 | msn.comJCPS busing decision reignited discussions about educational equity for future generationsApril 21, 2024 | seekingalpha.comGauzy Ltd. Aims For U.S. IPO As Revenue GrowsApril 21, 2024 | msn.comBerg Insight: The number of participants in electronic offender monitoring programmes reached 1.4 million in Europe and the Americas in 2023April 19, 2024 | uk.finance.yahoo.comGlobal Vision Care Market Projected to Surpass US$ 102 Billion by 2030 as Demand for Advanced Eye Care Solutions GrowsApril 19, 2024 | forbes.comFrom Concept To Impact: Navigating The Climate Tech Landscape With AI And RoboticsApril 18, 2024 | markets.businessinsider.comAutonomous Solutions, Inc. and VenHub Welcome Amazon Veteran Nader Kabbani to Its Board of AdvisorsApril 17, 2024 | msn.comConley’s Corner: A vision realized, but not yet complete for Timberwolves’ Mike ConleyApril 17, 2024 | finance.yahoo.comTELUS investing $135 million in CalgaryApril 16, 2024 | finance.yahoo.comDoorDash, Inc. (DASH) Interactive Stock Chart - Yahoo FinanceApril 15, 2024 | msn.com2024 "might be a turning point for Apple" — suppliers look elsewhere as Apple faces "frightening" question with no clear answerApril 14, 2024 | msn.comAEW's Dustin Rhodes Looks Back On WWE Gimmick GoldustApril 13, 2024 | msn.comCharlie Munger’s Critique of Tesla Sparks Reaction from Elon Musk: Agreement Amid DisappointmentApril 11, 2024 | nytimes.com‘Food, Inc. 2’ Review: A Second CourseApril 10, 2024 | markets.businessinsider.comOnum raises $28M to help businesses extract more value from their data at lower costsSee More Headlines Receive INSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InSite Vision and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:INSV CUSIPN/A CIK802724 Webwww.insitevision.com Phone+1-510-8658800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report INSV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of InSite Vision own? Based on aggregate information from My MarketBeat watchlists, some companies that other InSite Vision investors own include Aralez Pharmaceuticals (ARLZ), Novelion Therapeutics (NVLN), Portola Pharmaceuticals (PTLA) and iBio (IBIO). How do I buy shares of InSite Vision? Shares of INSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INSV) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InSite Vision Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
